The study maps the RNA-binding domain of HIV-1 Tat, demonstrating that the N-terminal 59 amino acids are required for binding to TAR RNA in vivo.
Answers are grounded in this paper and cite their sources.
No immediate clinical impact on HIV care; leaves open Tat-targeted transcription inhibitors pending human validation.
Transcriptional trans-activation of the human immunodeficiency virus type 1 long terminal repeat requires that the virally encoded Tat effector interacts with its target trans-activation response element (TAR) RNA stem-loop. Although the arginine-rich region of Tat from amino acids 49 to 59 is sufficient to bind to TAR RNA in vitro, the RNA-binding domain of Tat has not been defined in vivo. Human immunodeficiency virus type 1 also encodes the Rev protein, which acts through an RNA stem-loop called the Rev-response element to transport unspliced and singly spliced viral RNA species from the nucleus to the cytoplasm. To map the RNA-binding domain of Tat, we performed assays that relied on Rev function using the heterologous RNA-tethering mechanism of Tat and the TAR. By examining the effects of selected targeted mutations of Tat on the abilities of hybrid Tat/Rev proteins to rescue the expression of unspliced mRNA via the TAR, we demonstrated that residues throughout the N-terminal 59 amino acids of Tat are required for binding of Tat and TAR RNA in vivo.
No takes yet. Share an insight, caveat, or question.
Luo et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: